您搜索了: hiperparatiroidizmom (斯洛文尼亚语 - 英语)

demografske in izhodiščne značilnosti so bile reprezentativne za populacijo dializnih bolnikov s sekundarnim hiperparatiroidizmom.
demographic and baseline characteristics were representative of the dialysis patient population with secondary hpt.

rezultati dodatnih študij so podprli uporabo zdravila mimpara pri zdravljenju hiperkalciemije pri bolnikih s primarnim hiperparatiroidizmom.
the results of the additional studies supported the use of mimpara for hypercalcaemia in patients with primary hyperparathyroidism.

pri bolnikih s paratiroidnim karcinomom ali primarnim hiperparatiroidizmom je priporočeni začetni odmerek zdravila mimpara za odrasle 30 mg dvakrat dnevno.
in patients with parathyroid carcinoma or primary hyperparathyroidism, the recommended starting dose of mimpara for adults is 30 mg twice a day.

v nadaljnjih treh študijah so v času do enega leta primerjali učinkovitost zdravila parareg z učinkovitostjo placeba pri skupno 136 bolnikih s primarnim hiperparatiroidizmom.
a further three studies compared the effectiveness of parareg and placebo in a total of 136 patients with primary hyperparathyroidism over up to a year.

29 bolnikov s paratiroidnim karcinomom in 17 bolnikov s primarnim hiperparatiroidizmom, pri katerih ni bilo mogoče odstraniti obščitnic ali pri katerih kirurška odstranitev obščitnic ni bila učinkovita.
parareg has also been studied in a study involving 46 patients with hypercalcaemia, including 29 with parathyroid carcinoma and 17 with primary hyperparathyroidism who could not have their parathyroid glands removed or in whom surgery to remove the parathyroid glands was not effective.

če imate visoke ravni kalcija v krvi ali druge motnje fosfokalcijeve presnove; če imate druge bolezni kosti (vključno s hiperparatiroidizmom in pagetovo boleznijo);
if you suffer from high calcium levels in your blood or other disturbances in the calcium- phosphor metabolism; if you have other bone disease (including hyperparathyroidism or paget’s disease);

podatki raziskovalnih študij pri bolnikih s kronično boleznijo ledvic in sekundarnim hiperparatiroidizmom brez dializnega zdravljenja kažejo, da cinakalcet zniža koncentracijo pth v podobni meri kot pri bolnikih s končno odpovedjo ledvic in sekundarnim hiperparatiroidizmom, ki so na dializi.
investigational studies in patients with ckd and secondary hpt not undergoing dialysis indicated that cinacalcet reduced pth levels to a similar extent as in patients with esrd and secondary hpt receiving dialysis.

zdravilo mimpara so proučevali tudi v študiji, ki je vključevala 46 bolnikov s hiperkalciemijo, od tega 29 bolnikov s paratiroidnim karcinomom in 17 bolnikov s primarnim hiperparatiroidizmom, pri katerih obščitnic ni bilo mogoče odstraniti ali pri katerih kirurška odstranitev obščitnic ni bila učinkovita.
mimpara has also been studied in a study involving 46 patients with hypercalcaemia, including 29 with parathyroid carcinoma, and 17 with primary hyperparathyroidism who could not have their parathyroid glands removed or in whom surgery to remove the parathyroid glands was not effective.

primarnim hiperparatiroidizmom, pri katerih bi bila glede na koncentracijo kalcija v serumu indicirana paratiroidektomija (kot je opredeljeno v ustreznih smernicah za zdravljenje), a ta pri njih ni klinično primerna ali je kontraindicirana.
primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.

v ključni študiji je 46 bolnikov (29 s paratiroidnim karcinomom in 17 s primarnim hiperparatiroidizmom (pri katerih paratiroidektomija ni bila uspešna ali je bila kontraindicirana) dobivalo cinakalcet do 3 leta (povprečje pri bolnikih s paratiroidnim karcinomom je bilo 328 dni, pri bolnikih s primarnim hiperparatiroidizmom pa 347 dni).
in a key study,46 patients (29 with parathyroid carcinoma and 17 with primary hpt (who had failed or had contraindications to parathyroidectomy) received cinacalcet for up to 3 years (mean of 328 days for patients with parathyroid carcinoma and mean of 347 days for patients with primary hpt)..